FDA Issues Revised Draft Guidance on Demonstrating Substantial Evidence of Effectiveness for Human Drugs and Biological Products
On June 22, 2026, the U.S. Department of Health and Human Services (HHS) unveiled Operation TrialBlazer, a department-wide effort to accelerate clinical research and development centered in the…
Read the full articleYou might also wanna read
HHS and FDA announce reforms to accelerate clinical trials and restore US research leadership
A welcome move from the FDA and HHS
writingruxandrabio.com·18d ago
HHS Launches Department-Wide Initiative to Revitalize US Leadership in Clinical Trials
HHS announced a coordinated department-wide effort to strengthen America’s leadership in clinical research.
hhs.gov·17d ago
FDA to launch pilot program to speed up early-stage clinical trials
Federal health officials aim to speed up drug development and better compete with China.
statnews.com·18d ago
FDA-awarded RMAT designations continue to surge in 2025, reveals GlobalData
Since the FDA first awarded a regenerative medicine advanced therapeutic (RMAT) designation in 2017, activity in this space remained relativ
The State of the U.S. Biomedical and Health Research Enterprise Strategies for Achieving a Healthier America
Final Book Now Available The U.S. biomedical research enterprise has played a vital role in advancing science, human health, and the economy
HLB liver cancer drug hits FDA setback again over manufacturing issues
HLB's hopes of bringing its liver cancer treatment to the US market have suffered another blow after the US Food and Drug Administration iss
Comments
Sign in to join the conversation.
No comments yet. Be the first.